DOCSLIB.ORG

Article in Press

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Article in Press ARTICLE IN PRESS Abstracts / Journal of the Neurological Sciences (2019) xxx–xxx 119 WCN19-1291 WCN19-1293 Poster shift 02 - Autoimmune disorders - Part I/CNS infections - Poster shift 02 - Autoimmune disorders - Part I/CNS infections - Part I/dementia - Part I/epilepsy - Part I/health economics and Part I/dementia - Part I/epilepsy - Part I/health economics and outcomes/neuroepidemiology and environmental and other outcomes/neuroepidemiology and environmental and other Different outcome from different approach of therapy by Comparative assesment of prognosis and frequency of acute plasmapheresis and immunotherapy in GBS patients inflammatory demyelinating polyneuropathy in Turkish and Syrian patients between 2012 AND 2018 A. Wirathmawati, B. Munir, S. Nandar Faculty of Medicine, Brawijaya University, Neurology Department, E.E. Okuyucu, D. Selcuk Malang, Indonesia Mustafa Kemal University Hospital, Neurology, Hatay, Turkey Objective Purpose To present different outcome of Guillain Barre Syndrome therapy To compare the frequencies and prognoses of the Turkish and between plasmapheresis and immunotherapy. Syrian patients diagnosed with, and treated for acute inflammatory demyelinating polyneuropathy (AIDP). Background Plasmapheresis and IVIG Therapy are standard therapy for GBS, Method but in Indonesia there is not any recorded data to show effectivity of The whole data of 40 patients with AIDP, 20 Turkish and 20 both plasmapheresis and IVIG. Syrian, who have been hospitalized between 2012–2018 in the Neurology Clinic of Mustafa Kemal University Medical Faculty, have Methods been evaluated retrospectively, and analyzed. Prospective serial case report of 50 GBS patient in Saiful Anwar General Hospital from January 2018 to January 2019, with EMG and Findings LCS analysis as tools to establish the GBS diagnose and GBS disability The average age were 43,65 ± 13,95. In 60% of the patients, upper score parameter for asses the improvement of therapy. Statistical respiratory infection has been detected as most common factor. The method using t paired test. admission time to hospital for Syrian patients was 11,3 ± 5,7 days, it was 6,5 ±4,0 days for the Turkish patients, and the difference was Results significant. The hospitalization and discharge MRC scores in Turkish 50 consecutive patients were included in the study and consist of patients were higher and the difference was statistically significant 32 men and 18 women. 1 patient was died at ER. Mean age was 40.5 (p b 0,001). While the Syrian patients with 3 or below AIDP disability years, mean of hospitalization was 15 days. Types of GBS were divide (Hughes) score was 30%, it was 100% in Turkish patients (p b 0,001). in 3 type; AMAN in 36%, AMSAN in 46% and SMF in 14%. Plasmapheresis as therapy was in 79% of patient, immunotherapy Result was 12% and the rest patient was refused to therapy and got Hyponatremia, low hospitalization MRC score, late admission to supportive therapy. Disability score were assessed at admission, hospital are determined as bad prognostic factors. In Syrian patients, discharge and 6 months follow up. Mean disability score from GBS hyponatremia was seen more respect to Turkish patients. The onset in hospital admission was 4.1. Plasmapheresis shown 60% hospitalization-discharge MRC scores of Syrian patients were lower, better outcome in our patients but IVIG only shown approximately and Hughes scores were higher respect to Turkish patients. In Syrian 30%. patients the need of intensive care and sequel ratio was higher, while the response to treatment was higher in Turkish patients. In Syrian Conclusion patients, AIDP progresses with worse prognosis than Turkish Plasmapheresis shown better outcome than IVIG in GBS patients, and their response to treatment is worse. We hypothesize treatment. that AIDP can be seen easier due to the suppression of the immunological picture during and after the war. Keyword: Guillain Barre Syndrome, Disability score, Plasmapheresis, Intravenous immunoglobulin doi:10.1016/j.jns.2019.10.992 References [1] John R. Pikula, Guillan Barre Syndrome: a case report, J. Can. WCN19-1294 Chiropr. Assoc. 39 (2) (1995 Jun) 80–83. [2] Hugh J. Wilson, Bart C. Jacobs, Pieter A. Van Doom, Guillain Barrre Syndrome, Lancet 388 (2016) 717–727. Poster shift 02 - Autoimmune disorders - Part I /CNS infections - Part I / dementia - Part I /epilepsy - Part I / health economics and outcomes / neuroepidemiology and environmental and other doi:10.1016/j.jns.2019.10.991 Epidemiological watch on epilepsy at the research and mental health laboratory (LNSM) Antananarivo, Madagascar: A 2 years study ARTICLE IN PRESS 120 Abstracts / Journal of the Neurological Sciences (2019) xxx–xxx F. Ravelosaona, R.S. Razafindrasata, N.F. Rasaholiarison, J. cUniversity of Bari Aldo Moro, Basic Medicine- Neuroscience- and Sense Razafimahefa, A.D. Tehindrazanarivelo Organs, Bari, Italy HU Befelatanana, Neurology, Antananarivo, Madagascar dPia Fondazione Cardinale G. Panico, Department of ClinicalResearch in Neurology, Tricase LE, Italy Introduction Epilepsy is the most frequently encountered neurological pathol- Background ogy in the world. In sub-Saharan Africa the prevalence varies We report a 82-year-old woman, who gradually started to between 2.2 and 58/1000 with an average of 15.83. present in 2015 cognitive impairment (forgetfulness, impaired attention) with fluctuating course and behavioural symptoms Objective (auditory and visual hallucinations, apathy). Since Spring 2016, To determine the epidemio-clinical profile of epilepsy in a reference progressive slowness of movements was observed. Since Autumn center that performs a profound clinical and paraclinic analysis such as 2016, she felt that another person was inside her and was telling the LNSM and comparing them to data from non-specificcenter. her what to do. Neurological examination showed ipomimia, akinesia and rigidity in all limbs, postural abnormalities, difficulties Methods in gait. A retrospective descriptive study was conducted between January 2013 and December 2014. Patient records for EEG with epilepsy Methods diagnosis and other sites : data from statistical directories of non- The patient underwent an extensive neuropsychological assess- specific centers in all regions of Madagascar, with direct standard- ment, MRI, Single Photon Emission Tomography (SPET) with ization of rates of prevalence and specific incidence of age of 2 dopamine transporter (DAT) scan. populations by a reference population. Results Results In July 2016, MRI scan showed cortical and subcortical atrophy Crude epilepsy prevalence rate: 572%o and 698%o/year in 2013 and small areas of increased signal intensity in centrum semiovalis of and 2014 seen at the LNSM. 15%o to non-specific center. Gross both cerebral hemispheres on FLAIR sequences. In September 2016, incidence in 2013 and 2014: 49988/100000 people/year and 50775/ neuropsychological testing documented cognitive impairment, 100,000 persons/year. Respectively 38/100000 persons/year and 88/ mainly characterised by deficits of executive functions and episodic 100000 persons/year at the level of non-specific center with the memory. In June 2017, about 2 years after disease onset, DAT-scan highest specific incidence in the 5 to 14 year age group diagnostic. did not show decreased DAT striatal uptake. So far, the patient The symptomatic form predominated. refused a repeat DAT-scan SPECT. Discussion Discussion This result seen at LNSM are largely high compared to those of According to current diagnostic criteria, a clinical diagnosis of the non-specific center issued by the statistical directories and this probable Dementia with Lewy bodies can be made in this patient. difference persists despite the standardization with respect to age The absence of abnormalities on DAT-scan, reported in a low with change in the peak incidence of Epilepsy. Explained by the fact percentage of patients with neuropathologically confirmed diagnosis that in specific center like the LNSM the diagnosis of epilepsy is of DLB, may arise from a less marked neuronal loss in the substantia electroclinical and more thorough. nigra in such patients, who may show abnormal DAT-scan on follow- up. Conclusion Our study confirms the importance of a specific diagnostic center Conclusions to better handle epilepsy. This case supports the view that DLB in early stages may show different patterns of presentation from clinical and neuropatholog- doi:10.1016/j.jns.2019.10.993 ical viewpoints. doi:10.1016/j.jns.2019.10.994 WCN19-1299 Poster shift 02 - Autoimmune disorders - Part I /CNS infections - WCN19-1306 Part I / dementia - Part I /epilepsy - Part I / health economics and outcomes / neuroepidemiology and environmental and other Poster shift 02 - Autoimmune disorders - Part I /CNS infections - Part I / dementia - Part I /epilepsy - Part I / health economics and Multiple personality and hallucinations in a patient with normal outcomes / neuroepidemiology and environmental and other dat-scan spect fulfilling diagnostic criteria for probable dementia with lewy bodies Comparative analysis of the psychoemotional and cognitive spectrum in various forms of parkinson's disease A. Danielea, G. Lacidognaa, C. Emanuelea, M. Orsinia, D. Seripab,G. Paronib, G. Logroscinoc, F. Panzad S. Djalilovaa, Z. Ibodullayevb, D. Abdullayevab aCatholic University of Sacred Hearth, Neurology, Rome, Italy aAssistent, Neurological diseases, Tashkent, Uzbekistan bFondazione IRCCS Casa Sollievo della Sofferenza, Complex Unit of bTashkent Medical Academy, Neurological diseases,
Load more

Recommended publications
  • Pain Improvement in Parkinson's Disease Patients Treated
    Journal of Personalized Medicine Article Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study Diego Santos García 1,* , Rosa Yáñez Baña 2, Carmen Labandeira Guerra 3, Maria Icíar Cimas Hernando 4, Iria Cabo López 5 , Jose Manuel Paz González 1, Maria Gema Alonso Losada 3, Maria José Gonzalez Palmás 5, Carlos Cores Bartolomé 1 and Cristina Martínez Miró 1 1 Department of Neurology, CHUAC, Complejo Hospitalario Universitario de A Coruña, 15006 A Coruña, Spain; [email protected] (J.M.P.G.); [email protected] (C.C.B.); [email protected] (C.M.M.) 2 Department of Neurology, CHUO, Complejo Hospitalario Universitario de Ourense, 32005 Ourense, Spain; [email protected] 3 Department of Neurology, CHUVI, Complejo Hospitalario Universitario de Vigo, 36213 Vigo, Spain; [email protected] (C.L.G.); [email protected] (M.G.A.L.) 4 Hospital de Povisa, 36211 Vigo, Spain; [email protected] 5 Department of Neurology, CHOP, Complejo Hospitalario Universitario de Pontevedra, 36002 Pontevedra, Spain; [email protected] (I.C.L.); [email protected] (M.J.G.P.) * Correspondence: [email protected]; Tel.: +34-646-173-341 Citation: Santos García, D.; Yáñez Abstract: Background and objective: Pain is a frequent and disabling symptom in Parkinson’s disease Baña, R.; Labandeira Guerra, C.; (PD) patients. Our aim was to analyze the effectiveness of safinamide on pain in PD patients from Cimas Hernando, M.I.; Cabo López, the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR I.; Paz González, J.M.; Alonso Losada, symptoms in Parkinson´s disease patients) study.
    [Show full text]
  • Taste and Smell Disorders in Clinical Neurology
    TASTE AND SMELL DISORDERS IN CLINICAL NEUROLOGY OUTLINE A. Anatomy and Physiology of the Taste and Smell System B. Quantifying Chemosensory Disturbances C. Common Neurological and Medical Disorders causing Primary Smell Impairment with Secondary Loss of Food Flavors a. Post Traumatic Anosmia b. Medications (prescribed & over the counter) c. Alcohol Abuse d. Neurodegenerative Disorders e. Multiple Sclerosis f. Migraine g. Chronic Medical Disorders (liver and kidney disease, thyroid deficiency, Diabetes). D. Common Neurological and Medical Disorders Causing a Primary Taste disorder with usually Normal Olfactory Function. a. Medications (prescribed and over the counter), b. Toxins (smoking and Radiation Treatments) c. Chronic medical Disorders ( Liver and Kidney Disease, Hypothyroidism, GERD, Diabetes,) d. Neurological Disorders( Bell’s Palsy, Stroke, MS,) e. Intubation during an emergency or for general anesthesia. E. Abnormal Smells and Tastes (Dysosmia and Dysgeusia): Diagnosis and Treatment F. Morbidity of Smell and Taste Impairment. G. Treatment of Smell and Taste Impairment (Education, Counseling ,Changes in Food Preparation) H. Role of Smell Testing in the Diagnosis of Neurodegenerative Disorders 1 BACKGROUND Disorders of taste and smell play a very important role in many neurological conditions such as; head trauma, facial and trigeminal nerve impairment, and many neurodegenerative disorders such as Alzheimer’s, Parkinson Disorders, Lewy Body Disease and Frontal Temporal Dementia. Impaired smell and taste impairs quality of life such as loss of food enjoyment, weight loss or weight gain, decreased appetite and safety concerns such as inability to smell smoke, gas, spoiled food and one’s body odor. Dysosmia and Dysgeusia are very unpleasant disorders that often accompany smell and taste impairments.
    [Show full text]
  • Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing
    Allergy Asthma Immunol Res. 2019 Jan;11(1):e18 https://doi.org/10.4168/aair.2019.11.e18 pISSN 2092-7355·eISSN 2092-7363 Original Article Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing Kyung Hee Park,1,2 Sang Chul Lee,1,2 Ji Eun Yuk,2 Sung-Ryeol Kim,1,2 Jae-Hyun Lee,1,2 Jung-Won Park1,2* 1Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea Received: Aug 6, 2018 ABSTRACT Revised: Sep 10, 2018 Accepted: Sep 22, 2018 Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing Correspondence to muscle spasm and pain. For more effective pain control, eperisone is usually prescribed Jung-Won Park, MD, PhD together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may Division of Allergy and Immunology, have been overlooked as the cause of anaphylaxis compared with NSAIDs. This study aimed Department of Internal Medicine, Yonsei to analyze the adverse drug reaction (ADR) reported in Korea and suggest an appropriate University College of Medicine, 50-1 Yonsei-ro, diagnostic approach for eperisone-induced anaphylaxis. Seodaemun-gu, Seoul 03722, Korea. Tel: +82- 2-2228-1961; Fax: +82-2-393-6884; Methods: We reviewed eperisone-related pharmacovigilance data (Korea Institute of Drug E-mail: [email protected] Safety-Korea Adverse Event Reporting System [KIDS-KAERS]) reported in Korea from 2010 to 2015. ADRs with causal relationship were selected. Clinical manifestations, severity, Copyright © 2019 The Korean Academy of outcomes, and re-exposure information were analyzed.
    [Show full text]
  • Additional Antidepressant Pharmacotherapies According to A
    orders & is T D h e n r Werner and Coveñas, Brain Disord Ther 2016, 5:1 i a a p r y B Brain Disorders & Therapy DOI: 10.4172/2168-975X.1000203 ISSN: 2168-975X Review Article Open Access Additional Antidepressant Pharmacotherapies According to a Neural Network Felix-Martin Werner1, 2* and Rafael Coveñas2 1Higher Vocational School of Elderly Care and Occupational Therapy, Euro Academy, Pößneck, Germany 2Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla y León (INCYL), University of Salamanca, Salamanca, Spain Abstract Major depression, a frequent psychiatric disease, is associated with neurotransmitter alterations in the midbrain, hypothalamus and hippocampus. Deficiency of postsynaptic excitatory neurotransmitters such as dopamine, noradrenaline and serotonin and a surplus of presynaptic inhibitory neurotransmitters such as GABA and glutamate (mainly a postsynaptic excitatory and partly a presynaptic inhibitory neurotransmitter), can be found in the involved brain regions. However, neuropeptide alterations (galanin, neuropeptide Y, substance P) also play an important role in its pathogenesis. A neural network is described, including the alterations of neuroactive substances at specific subreceptors. Currently, major depression is treated with monoamine reuptake inhibitors. An additional therapeutic option could be the administration of antagonists of presynaptic inhibitory neurotransmitters or the administration of agonists/antagonists of neuropeptides. Keywords: Acetylcholine; Bupropion; Dopamine; GABA; Galanin; in major depression and to point out the coherence between single Glutamate; Hippocampus; Hhypothalamus; Major depression; neuroactive substances and their corresponding subreceptors. A Midbrain; Neural network; Neuropeptide Y; Noradrenaline; Serotonin; question should be answered, whether a multimodal pharmacotherapy Substance P with an agonistic or antagonistic effect at several subreceptors is higher than the current conventional antidepressant treatment.
    [Show full text]
  • Efficacy and Tolerability of Eperisone in Patients with Spastic Palsy: a Cross-Over, Placebo-Controlled Dose-Ranging Trial
    European Review for Medical and Pharmacological Sciences 2009; 13: 365-370 Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial N. BRESOLINA, C. ZUCCAB, A. PECORIC AInstitute of Clinical Neurology, University of Milan, I.R.C.C.S. Ospedale Maggiore Policlinico, Milan (Italy) BNeurophysiopathology Unit, IRCCS “E. Medea”, Bosisio Parini (LC) (Italy) CMedical Department Eisai Srl, San Donato Milanese, Milano (Italy) Abstract. – Background and Objectives: Introduction Central muscle relaxants are a clinical option in patients with spastic palsy. Eperisone is a cen- tral muscle relaxant used in several conditions, Spastic palsy is a clinical condition character- but its therapeutic potential in spastic palsy ized by a velocity-dependent increase of muscle needs to be verified. This dose-ranging trial tone due to “parapyramidal” disturbance of the compares two doses of eperisone in patients inhibitory afferents to the second motor neuron1. with spastic palsy associated to cerebral or spinal diseases. This condition may represent a major impedi- Patients and Methods: In this randomized, ment to a full functional recovery and social re- placebo-controlled, double-blind, three-way habilitation in patients with lesions of the pyra- cross-over study, patients (18-75 years) with midal system, which could follow different dis- spastic palsy received eperisone 150 mg/day, eases, as stroke or multiple sclerosis. eperisone 300 mg/day, or placebo for 8 weeks. Central muscle relaxants, such as baclofen, ti- Treatment periods lasted for 14 days. Objective zanidine, diazepam and dantrolene, represent an clinical parameters (intensity of spasticity and physiological reflexes) and functional parame- interesting clinical option in patients with spastic ters (walking capability, capability to climb palsy, since they reduce spasticity and improve stairs, rigidity) were measured.
    [Show full text]
  • Interface of Epilepsy and Sleep Disorders
    Seizure 1999; 8: 97 –102 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Article No. seiz.1998.0257, available online at http://www.idealibrary.com on provided by Elsevier - Publisher Connector Interface of epilepsy and sleep disorders Roy G. Beran, Menai J. Plunkett & Gerard J. Holland St Lukes Hospital Telemetry and Sleep Centre, St Lukes Hospital, 18 Roslyn Street, Potts Point, NSW 2011, Australia Correspondence to: Dr Roy G. Beran, Suite 5, 6th Floor, 12 Thomas Street, Chatswood, NSW 2067, Australia Obstructive sleep apnoea was first brought to prominence by Henri Gastaut, a French epileptologist. Since that time the interface between epilepsy and sleep disorders has received less attention than might be justified, recognizing that sleep deprivation is a poignant provocateur for seizures. Sleep deprivation is often used as a diagnostic procedure during electroencephalography (EEG) when waking EEG has failed to demonstrate abnormality. Patients referred to an outpatient neurological clinic for evaluation of possible seizures in whom sleep disorder was suspected, either due to snoring during the EEG or based on history, were evaluated with all-night diagnostic polysomnography (PSG) and appropriate intervention administered as indicated. Patient and seizure demography, sleep disorder and response to therapy were reviewed and the interface explored. Fifty patients aged between 10 and 83 years underwent PSG. Approximately half were diagnosed with epilepsy and almost three-quarters had sleep disorders sufficiently intrusive to require therapy (either continuous positive air pressure (CPAP) or medication). With co-existence of epilepsy and sleep disorders, proper management of sleep disorders provided significant benefit for seizure control.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Effect of Nutrition on Neurodegenerative Diseases. a Systematic Review
    Nutritional Neuroscience An International Journal on Nutrition, Diet and Nervous System ISSN: 1028-415X (Print) 1476-8305 (Online) Journal homepage: https://www.tandfonline.com/loi/ynns20 Effect of nutrition on neurodegenerative diseases. A systematic review Vittorio Emanuele Bianchi, Pomares Fredy Herrera & Rizzi Laura To cite this article: Vittorio Emanuele Bianchi, Pomares Fredy Herrera & Rizzi Laura (2019): Effect of nutrition on neurodegenerative diseases. A systematic review, Nutritional Neuroscience, DOI: 10.1080/1028415X.2019.1681088 To link to this article: https://doi.org/10.1080/1028415X.2019.1681088 Published online: 04 Nov 2019. Submit your article to this journal Article views: 23 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ynns20 NUTRITIONAL NEUROSCIENCE https://doi.org/10.1080/1028415X.2019.1681088 REVIEW Effect of nutrition on neurodegenerative diseases. A systematic review Vittorio Emanuele Bianchi a, Pomares Fredy Herrerab and Rizzi Laurac aEndocrinology and Metabolism, Clinical Center Stella Maris Falciano, Falciano, San Marino; bDirector del Centro de Telemedicina, Grupo de investigación en Atención Primaria en salud/Telesalud, Doctorado en Medicina /Neurociencias, University of Cartagena, Colombia; cMolecular Biology, School of Medicine and Surgery, University of Milano-Bicocca, Monza Brianza, Italy ABSTRACT KEYWORDS Neurodegenerative diseases are characterized by the progressive functional loss
    [Show full text]
  • Spinal Cord in Motor Neuron Diseases Using a Multi-Parametric MRI Approach
    Université Pierre et Marie Curie Cerveau Cognition Comportement Laboratoire d’Imagerie Biomédicale / Systèmes Dynamiques Anatomo-Fonctionnels chez l’Homme Thèse de Doctorat en Neurosciences Présentée par Mohamed-Mounir EL MENDILI Analysis of the structural integrity of the spinal cord in motor neuron diseases using a multi-parametric MRI approach Dirigée par Véronique MARCHAND-PAUVERT et Pierre-François PRADAT Présentée et soutenue le 13 Décembre 2016 devant le jury composé de Devant un jury composé de : M. Peter BEDE (PU-PH) Trinity College Dublin, Irland Rapporteur Mme. Virginie CALLOT (DR) Aix-Marseille Université Rapporteur M. Philippe CORCIA (PU-PH) Université François-Rabelais, Tours Examinateur M. Stéphane LEHERICY (PU-PH) Université Paris VI Examinateur Mme. Véronique MARCHAND-PAUVERT (DR) Université Paris VI Directeur de thèse M. Pierre-Francois PRADAT (PH) Université Paris VI Co-directeur de thèse This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. À tous les patients atteints d’une des maladies du motoneurone Contents Contents ..................................................................................................................................... i Remerciements .................................................................................................................... iii List of Tables .......................................................................................................................... iv List of Figures ........................................................................................................................
    [Show full text]
  • A Systematic Review of Nutritional Risk Factors of Parkinson's Disease
    Nutrition Research Reviews (2005), 18, 259–282 DOI: 10.1079/NRR2005108 q The Authors 2005 A systematic review of nutritional risk factors of Parkinson’s disease Lianna Ishihara* and Carol Brayne Department of Public Health and Primary Care, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 2SR, UK A wide variety of nutritional exposures have been proposed as possible risk factors for Parkinson’s disease (PD) with plausible biological hypotheses. Many studies have explored these hypotheses, but as yet no comprehensive systematic review of the literature has been available. MEDLINE, EMBASE, and WEB OF SCIENCE databases were searched for existing systematic reviews or meta-analyses of nutrition and PD, and one meta-analysis of coffee drinking and one meta-analysis of antioxidants were identified. The databases were searched for primary research articles, and articles without robust methodology were excluded by specified criteria. Seven cohort studies and thirty-three case–control (CC) studies are included in the present systematic review. The majority of studies did not find significant associations between nutritional factors and PD. Coffee drinking and alcohol intake were the only exposures with a relatively large number of studies, and meta-analyses of each supported inverse associations with PD. Factors that were reported by at least one CC study to have significantly increased consumption among cases compared with controls were: vegetables, lutein, xanthophylls, xanthins, carbohydrates, monosaccharides, junk food, refined sugar, lactose, animal fat, total fat, nuts and seeds, tea, Fe, and total energy. Factors consumed significantly less often among cases were: fish, egg, potatoes, bread, alcohol, coffee, tea, niacin, pantothenic acid, folate and pyridoxine.
    [Show full text]
  • Efficacy and Tolerability of Eperisone Versus Tizanidine in Patients Suffering from Low Back Pain with Muscle Spasm
    International Journal of Research in Medical Sciences Khan AF et al. Int J Res Med Sci. 2017 Jun;5(6):2694-2700 www.msjonline.org pISSN 2320-6071 | eISSN 2320-6012 DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172472 Original Research Article Efficacy and tolerability of eperisone versus tizanidine in patients suffering from low back pain with muscle spasm Abdul F. Khan1*, Khaneta Parveen2, Abdul S. Khan3 1Consultant Physician and Diabetologist, Mumbai, Maharashtra, India 2Department of Pathology and Blood Bank, Kohinoor Hospital, Mumbai, Maharashtra, India 3Department of Cardiology, Prince Sultan Hospital, Riyadh, KSA Received: 05 April 2017 Accepted: 28 April 2017 *Correspondence: Dr. Abdul F. Khan, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Low back pain (LBP), a high prevalent condition, is usually associated with 'muscle spasm' that is responsible for giving rise to pain. Eperisone hydrochloride is widely used for treatment associated muscle stiffness and pain. The aim of the study was to compare the efficacy and safety of eperisone tablets 50 mg three times daily versus tizanidine 2 mg tablets thrice daily for the treatment of low back pain with muscle spasm. Methods: The study was carried in 50 patients from a private hospital at Mumbai. Only patients satisfying the inclusion criteria were enrolled into the study. Subjects suffering from low back pain with spasm were divided in two groups.
    [Show full text]
  • WO 2012/172413 Al 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/172413 Al 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: (74) Agent: NAIR, Manoj Vasudevan; M/s Lex Orbis (Intel A61K 9/20 (2006.01) A61K 31/4453 (2006.01) lectual Property Practice), 709/710, Tolstoy House, 15-17 A61K 31/196 (2006.01) A61K 47/12 (2006.01) Tolstoy Marg, New Delhi 110 001 (IN). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/IB20 12/00 1159 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) Date: International Filing CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 15 June 2012 (15.06.2012) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 1759/MUM/201 1 16 June 201 1 (16.06.201 1) IN SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]